Eric Bjerkholt Purchases 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt purchased 2,000 shares of the company’s stock in a transaction dated Wednesday, March 27th. The shares were acquired at an average price of $24.80 per share, for a total transaction of $49,600.00. Following the purchase, the chief financial officer now directly owns 14,000 shares in the company, valued at $347,200. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Eric Bjerkholt also recently made the following trade(s):

• On Monday, March 18th, Eric Bjerkholt purchased 2,000 shares of Mirum Pharmaceuticals stock. The shares were acquired at an average price of $25.80 per share, for a total transaction of $51,600.00.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock opened at $25.12 on Friday. The company’s 50-day moving average price is $27.46 and its 200-day moving average price is $29.20. Mirum Pharmaceuticals, Inc. has a twelve month low of $21.83 and a twelve month high of $35.56. The company has a debt-to-equity ratio of 1.23, a quick ratio of 4.19 and a current ratio of 4.45.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.32). The firm had revenue of $69.55 million for the quarter, compared to the consensus estimate of $66.73 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. Analysts predict that Mirum Pharmaceuticals, Inc. will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several hedge funds have recently modified their holdings of the business. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Mirum Pharmaceuticals by 111.9% in the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 211,949 shares of the company’s stock worth $6,257,000 after purchasing an additional 111,949 shares during the period. Vanguard Group Inc. lifted its position in shares of Mirum Pharmaceuticals by 46.2% in the 4th quarter. Vanguard Group Inc. now owns 2,476,244 shares of the company’s stock worth $73,099,000 after purchasing an additional 782,901 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Mirum Pharmaceuticals by 89.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 456,318 shares of the company’s stock worth $13,471,000 after purchasing an additional 215,542 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Mirum Pharmaceuticals by 3,544.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,164,682 shares of the company’s stock worth $34,383,000 after purchasing an additional 1,132,723 shares during the period. Finally, Blue Owl Capital Holdings LP lifted its position in shares of Mirum Pharmaceuticals by 109.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 10,013 shares of the company’s stock worth $296,000 after purchasing an additional 5,229 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. HC Wainwright lifted their price target on shares of Mirum Pharmaceuticals from $45.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, March 14th. SVB Leerink lowered their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Monday, March 18th. Cantor Fitzgerald restated an “overweight” rating and set a $35.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, February 29th. Raymond James lowered their target price on shares of Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, December 19th. Finally, JMP Securities lifted their target price on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, March 14th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $52.11.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.